A regulator, a court or a government decision holds the price of these companies down. The outcome can take years, and the date is often not in the company's hands. A ruling, a settlement or a new law is the event that can change the picture.
This is information, not advice (see the disclaimer).
Deep below intrinsic value · Analysts: Leaning bullish
The farm machinery cycle is at a low point and farm incomes are weak, so the gap closes slowly as farmers buy machines again in 2027 and 2028.
Next checkpoint: Full-year 2026 results and 2027 outlook (Feb 9, 2027 (estimate))
Deep below intrinsic value · Analysts: Bullish
Failed partner heart trials cut Ionis's royalty value and the TRYNGOLZA launch is slow, so the gap closes only if its own launches and new partner approvals grow over the next four to eight quarters.
Next checkpoint: EU decision on TRYNGOLZA in severe hypertriglyceridemia (Q4 2026 (estimate))
Far below intrinsic value · Analysts: Bullish
The market prices AECOM for losses on one old Construction Management project and slower growth, and a clean project finish in early 2027 with steady design growth can close the gap.
Next checkpoint: Fiscal 2026 results: cash flow and fiscal 2027 guidance (Nov 16, 2026)
Far below intrinsic value · Analysts: Bullish
The market treats the AI spending of Alibaba as a cost, and fast Cloud growth can help, but the discount for US-China risk and the VIE structure will probably stay.
Next checkpoint: Fiscal Q2 2027 results: Cloud growth against capital spending (Nov 19, 2026)
Far below intrinsic value · Analysts: Very bullish
The market fears that AI answers will take clicks from Search, and steady Cloud and Search growth through early 2027 can close the gap.
Next checkpoint: Final judgment and appeals in the US ad tech case (Q4 2026 (estimate))
Far below intrinsic value · Analysts: Bullish
Prediction markets threaten DraftKings' licensed sports betting and raise its costs, and court limits on them or profitable Predictions growth by mid-2027 can close the gap.
Next checkpoint: Full-year 2026 results: Q4 Predictions spending and the 2027 outlook (Feb 5, 2027 (estimate))
Far below intrinsic value · Analysts: Bullish
Falling US profit, prediction markets, higher taxes and a new CEO hold Flutter down, so FanDuel must grow again and leverage must fall for the gap to close.
Next checkpoint: Brazil: Congress decision on the betting ban (Jan 2027 (estimate))
Far below intrinsic value · Analysts: Leaning bullish
A parts shortage forced a guidance cut, and the gap can close from 2027 if supply catches up with strong orders.
Next checkpoint: Securities class action lead-plaintiff deadline (Nov 23, 2026)
Far below intrinsic value · Analysts: Leaning bullish
The market prices Invitation Homes for slow rent growth and new limits on institutional owners of single-family homes, and better new lease rents with rules that leave its homes unchanged can close the gap.
Next checkpoint: Q4 2026 results and the 2027 guidance (Jan 28, 2027 (estimate))
Far below intrinsic value · Analysts: Leaning bullish
The market prices National Grid for the cost of its large investment plan and the risk of lower allowed returns, and EPS growth on guidance with stable ratings over the next three to five quarters can close the gap.
Next checkpoint: Full-year 2026/27 results: first year of the new plan (May 13, 2027 (estimate))
Far below intrinsic value · Analysts: Leaning bullish
Open-ended wildfire liability in California holds the price down, and without a durable legal reform the gap will probably not close before 2028.
Next checkpoint: CPUC proposed decision on Kincade and Dixie fire cost recovery (Nov 13, 2026 (estimate))
Far below intrinsic value · Analysts: Mixed
The market fears that strict Oregon rules will make the large investment plan of PGE hard to fund, and a changed holding company order with approval of the Washington purchase can close the gap.
Next checkpoint: OPUC response on the holding company conditions (Q4 2026 (estimate))
Well below intrinsic value · Analysts: Bullish
The market prices Couche-Tard for the risk that high fuel margins fall and for the debt of the Żabka deal, and steady margins, store sales growth and a smooth deal can close the gap.
Next checkpoint: Q2 fiscal 2027 results: fuel margins and store sales (Nov 24, 2026)
Well below intrinsic value · Analysts: Bearish
The market doubts that Ambev's beer growth lasts after the World Cup and fears Brazil's new alcohol tax, and steady volume with a neutral tax through 2027 can close the gap.
Next checkpoint: Selective Tax rates on beer (Q4 2026 (estimate))
Well below intrinsic value · Analysts: Bullish
The market doubts that defense budgets will grow as long as BAE's record backlog suggests, and clear UK funding with growth on guidance can close the gap.
Next checkpoint: FY 2026 results and 2027 guidance (Feb 18, 2027 (estimate))
Well below intrinsic value · Analysts: Leaning bullish
Investors fear that AI tools and tokenized securities will move work around Broadridge, so the gap closes slowly as recurring revenue and bookings keep growing.
Next checkpoint: Investor Day: new three-year objectives (Dec 8, 2026)
Well below intrinsic value · Analysts: Bullish
Corteva kept the old DuPont PFAS liabilities after the Vylor spin-off and states sued to stop it, so the gap closes slowly as courts and settlements limit the legal risk.
Next checkpoint: Seventh Circuit ruling on the restraining order (Q4 2026 (estimate))
Well below intrinsic value · Analysts: Bullish
A data breach brought vouchers, fines and Korean government pressure, and a margin recovery by mid-2027 without new large penalties can close the gap.
Next checkpoint: Q4 2026 results and 2027 outlook (Feb 3, 2027 (estimate))
Well below intrinsic value · Analysts: Bearish
Investors cannot measure Edison's Eaton Fire liability after California failed to pass wildfire reform, so settled claims and a new law in 2027 must come for the gap to close.
Next checkpoint: Eaton Fire compensation program: claim deadline (Nov 30, 2026)
Well below intrinsic value · Analysts: Very bullish
Investors fear that AI scoring and new US mortgage rules will cut the need for credit bureau data, so the gap closes slowly as Experian keeps organic growth inside its guided range.
Next checkpoint: H1 FY27 results: organic growth, margin and leverage (Nov 18, 2026)
Well below intrinsic value · Analysts: Leaning bullish
The market prices Ford for EV losses, tariffs, recalls and supply problems, and reaching its raised 2026 guidance with smaller EV losses in 2027 can close the gap over four to six quarters.
Next checkpoint: 2027 guidance: EBIT and Model e losses (Jan 28, 2027 (estimate))
Well below intrinsic value · Analysts: Mixed
Plant problems cut 2026 earnings and the debt-funded Tate & Lyle deal adds risk, and an Argo recovery with a clean deal closing in 2027 can close the gap.
Next checkpoint: Full-year 2026 results and 2027 outlook (Feb 5, 2027 (estimate))
Well below intrinsic value · Analysts: Bullish
A cut to US Omnipod growth, two Pod corrections and new patch pump rivals hurt trust in Insulet, so growth within the new guidance through early 2027 can close the gap.
Next checkpoint: Q4 2026 results and 2027 outlook (Feb 4, 2027 (estimate))
Well below intrinsic value · Analysts: Bullish
Lumentum's price now follows Marvell's all-stock offer and very fast AI optics growth, and only a closed merger and a strong Marvell price can lift its value.
Next checkpoint: Q2 fiscal 2027 results (Feb 2, 2027 (estimate))
Well below intrinsic value · Analysts: Very bullish
Chinese game rules, US-China tension and doubts about new hits keep a China discount on NetEase, so the gap will probably not close fully even with strong cash and growing games.
Next checkpoint: Q3 2026 results: games growth and new titles (Nov 19, 2026)
Well below intrinsic value · Analysts: Very bullish
The market doubts that all of Nvidia's demand is organic and now also weighs a board investigation of its CEO, and broad growth, a stable gross margin and a clean investigation can close the gap.
Next checkpoint: Fiscal Q3 2027 results: gross margin and customer breadth (Nov 17, 2026)
Well below intrinsic value · Analysts: Leaning bullish
The market prices PACCAR for a weak North American truck market and unclear emissions rules, and higher deliveries with a firm 2027 outlook over the next three to five quarters can close the gap.
Next checkpoint: Q4 2026 earnings: 2027 market outlook (Jan 27, 2027 (estimate))
Well below intrinsic value · Analysts: Leaning bullish
The market prices PDD Holdings for lower profits, trade and EU rule risk for Temu and China risk, and steady profit growth with a clear use for its large cash can close part of the gap over several quarters.
Next checkpoint: Q3 2026 results: profit trend (Nov 18, 2026 (estimate))
Well below intrinsic value · Analysts: Leaning bullish
A sudden pool channel stock cut, a CFO exit and a debt-funded Taco deal broke trust in Pentair, so a Pool recovery in the 2027 season can close the gap.
Next checkpoint: Q4 2026 results and 2027 outlook (Jan 27, 2027 (estimate))
Well below intrinsic value · Analysts: Leaning bullish
The market prices Rogers for high debt, a wireless price war and the cost of buying all of MLSE, and higher free cash flow with a Rogers Sports stake sale that cuts debt can close the gap.
Next checkpoint: Full-year 2026 results and 2027 guidance (Jan 23, 2027 (estimate))
Well below intrinsic value · Analysts: Bullish
Investors fear that AI agents will cut the paid seats SAP prices its cloud software around, and strong cloud growth through the 2027 upgrade cycle can close the gap.
Next checkpoint: Full-year 2026 results and 2027 outlook (Jan 28, 2027)
Well below intrinsic value · Analysts: Bullish
The market fears that China's antitrust rules cut Trip.com's hotel commissions, and steady domestic growth with fast international growth over 2027 can close the gap slowly.
Next checkpoint: Q3 2026 results: China hotels under the new rules (Nov 17, 2026 (estimate))
Below intrinsic value · Analysts: Leaning bullish
The market prices Alcoa for lower aluminum prices and the risk of the South32 asset purchase, and steady metal prices with a clean close in the first half of 2027 can close the gap.
Next checkpoint: Q4 2026 earnings: production and costs (Jan 15, 2027 (estimate))
Below intrinsic value · Analysts: Very bullish
The market prices Aptar for lower margins and the drop in emergency medicine sales, and a margin recovery as destocking ends in late 2026 under the new CEO can close the gap.
Next checkpoint: Q4 2026 earnings: end of destocking (Jan 29, 2027 (estimate))
Below intrinsic value · Analysts: Leaning bullish
The market prices Asbury for lower dealer profits and a costly software change, and lower costs in 2027 after the Tekion rollout ended in October 2026 can close the gap.
Next checkpoint: Q4 2026 earnings: first quarter after the rollout (Jan 27, 2027 (estimate))
Below intrinsic value · Analysts: Bullish
Low-yield bonds bought when rates were low hold back Bank of America's returns, and growing net interest income with ROTCE near its target in 2027 can close the gap.
Next checkpoint: Q4 2026 results and 2027 outlook (Jan 14, 2027 (estimate))
Below intrinsic value · Analysts: Very bullish
The market doubts that Boeing can raise production and turn its record backlog into cash on time, and steady 737 rates, the 777-9 certification and positive cash flow can close the gap over several years.
Next checkpoint: Q4 2026 results and 2027 outlook (Jan 27, 2027 (estimate))
Below intrinsic value · Analysts: Bullish
Investors fear that AI assistants will take travel bookings away from Booking.com, and steady room night growth with stable marketing costs can close the gap.
Next checkpoint: Q4 2026 results and 2027 outlook (Feb 3, 2027 (estimate))
Below intrinsic value · Analysts: Leaning bullish
The market fears that new drugs cannot replace Eliquis and Opdivo after their 2028 patent losses, and positive milvexian or Cobenfy readouts in early 2027 can close the gap.
Next checkpoint: Full-year 2026 results and 2027 guidance (Jan 29, 2027 (estimate))
Below intrinsic value · Analysts: Bullish
The market fears that medical costs and pressure on pharmacy benefits will cut CVS's profits again, and steady Aetna margins with lower debt over the next four to six quarters can close the gap.
Next checkpoint: 2027 guidance (Feb 4, 2027 (estimate))
Below intrinsic value · Analysts: Leaning bullish
The market prices Coinbase on crypto trading volume that swings with coin prices, and steady growth of subscription and services revenue can lift its value in a weak market.
Next checkpoint: Coinbase Pro relaunch and Q4 outlook (Q4 2026)
Below intrinsic value · Analysts: Bullish
Cummins trades below its intrinsic value because investors fear a truck downturn and doubt that data center demand lasts, and strong power generation results with stable truck markets can close the gap.
Next checkpoint: Q4 2026 results and the 2027 outlook (Feb 5, 2027 (estimate))
Below intrinsic value · Analysts: Bullish
The market prices Danone for slow growth in Europe, the 2026 infant formula recall and weak North American dairy, and a return to growth in these areas through 2027 can close the gap.
Next checkpoint: Full-year 2026 results and 2027 guidance (Jan 28, 2027 (estimate))
Below intrinsic value · Analysts: Bullish
Investors doubt that the investments of DoorDash and its purchase of Instacart will pay off, and continued order growth with higher margins and a clean Instacart closing can close the gap.
Next checkpoint: Q4 2026 results and 2027 outlook (Feb 17, 2027 (estimate))
Below intrinsic value · Analysts: Bullish
The market prices Elevance for high Medicaid costs and Medicare Advantage risk, and 2027 earnings growth from the 2026 baseline with a falling benefit expense ratio can close the gap.
Next checkpoint: Q4 2026 results and 2027 guidance (Jan 27, 2027 (estimate))
Below intrinsic value · Analysts: Mixed
The market prices Essex for slow rents in Southern California and doubt about Bay Area demand, and steady rent growth with low new supply in 2027 can close the gap over four to six quarters.
Next checkpoint: Q4 2026 results: 2027 guidance (Jan 27, 2027 (estimate))
Below intrinsic value · Analysts: Leaning bullish
The market doubts that GSK's new medicines can replace its HIV sales before patents expire from 2028, and the gap closes only as launches grow over several years.
Next checkpoint: FDA decision on neladalkib for ALK-positive lung cancer (Nov 27, 2026)
Below intrinsic value · Analysts: Leaning bullish
Investors doubt that HII can turn its large Navy backlog into profit and cash, and it must show positive cash flow and steady margins over the next two to three years for the gap to close.
Next checkpoint: Full-year 2026 results and 2027 outlook (Jan 29, 2027 (estimate))
Below intrinsic value · Analysts: Very bullish
Investors see a tobacco business that shrinks in volume and depends on price increases, so Imperial must show steady profit growth and profitable new products over several years to close the gap.
Next checkpoint: Fiscal 2026 results and fiscal 2027 outlook (Nov 17, 2026)
Below intrinsic value · Analysts: Mixed
The market fears that AI will lower demand for Infosys's IT services after a second guidance cut, and faster growth from its large deals with steady margins can close the gap over four to six quarters.
Next checkpoint: Q3 fiscal 2027 results: growth and the large deal ramp (Jan 23, 2027 (estimate))
Below intrinsic value · Analysts: Leaning bullish
Investors fear that free AI tools will take customers from TurboTax and Credit Karma, and the 2027 tax season is the main test of that fear.
Next checkpoint: Fiscal Q1 2027 earnings: first read before tax season (Nov 19, 2026)
Below intrinsic value (AI estimate) · Analysts: Bullish
The market weighs the high profits and dividends of Kaspi.kz against the risk of one country and currency and losses in Türkiye, and lower deposit costs with smaller Türkiye losses in 2027 can lift its value.
Next checkpoint: Shareholder vote on the Q3 2026 dividend (Dec 9, 2026)
Below intrinsic value · Analysts: Leaning bullish
The market weighs rising margins against the Respironics legal costs and a tariff refund that may not repeat, and a final settlement with steady margin gains in 2027 can lift its value.
Next checkpoint: Q4 2026 results and 2027 outlook (Feb 9, 2027 (estimate))
Below intrinsic value · Analysts: Mixed
The market prices Landstar for rising insurance and claims costs, and stable claim costs with the recovery in truck prices over the next four to six quarters can close the gap.
Next checkpoint: Q4 2026 results: insurance costs and truck prices (Jan 27, 2027 (estimate))
Below intrinsic value · Analysts: Bullish
Investors fear lower UK rates and the cost of motor finance redress at Lloyds, and steady hedge income with a redress cost within its provision can close the gap.
Next checkpoint: Full-year 2026 results and Accelerate 2030 targets (Jan 28, 2027 (estimate))
Below intrinsic value · Analysts: Leaning bullish
Investors doubt US defense funding and Lockheed Martin's cost control, so a full-year budget and quarters without new program losses must come for the gap to close.
Next checkpoint: End of the US stopgap budget (Dec 11, 2026)
Below intrinsic value · Analysts: Bullish
The market fears that AI spending is larger than the cash that ads earn, and paid revenue from Meta One and Muse over the next two to three quarters can close the gap if legal penalties stay small.
Next checkpoint: Q4 2026 results and 2027 capital spending guidance (Jan 21, 2027 (estimate))
Below intrinsic value · Analysts: Bullish
The market fears that MPS's AI server growth can stop fast, and steady growth in all end markets with no import ban from the Vicor case over three to five quarters can close the gap.
Next checkpoint: Q4 2026 results: AI server revenue and Q1 2027 guidance (Jan 29, 2027 (estimate))
Below intrinsic value · Analysts: Leaning bullish
The market doubts that Northrop can turn its record backlog into profit after fixed-price charges and the F/A-XX loss, and steady margins with no new charges can close the gap.
Next checkpoint: Full-year 2026 results and 2027 guidance (Jan 20, 2027 (estimate))
Below intrinsic value · Analysts: Very bullish
The market fears that Chinese rules will cut the Hong Kong and Mainland sales of Prudential, and double-digit growth in 2026 with steady visitor demand can close most of the gap.
Next checkpoint: Full-year 2026 results (Mar 18, 2027 (estimate))
Below intrinsic value · Analysts: Bullish
The market fears that the AI chip boom is near a peak for Qnity, and steady sales growth with lower debt and small PFAS costs over the next two to four quarters can close the gap.
Next checkpoint: Q4 2026 results and the 2027 guidance (Feb 4, 2027 (estimate))
Below intrinsic value · Analysts: Bullish
The market removed part of the war premium from RTX and still prices the GTF engine problem, and funded missile orders with fewer grounded GTF aircraft over two to four quarters can close the gap.
Next checkpoint: Q4 2026 results: 2027 outlook and GTF fleet (Jan 20, 2027 (estimate))
Below intrinsic value · Analysts: Mixed
Range now trades on its all-stock merger with EQT, and a close in Q1 2027 with the planned synergies can close the gap, while gas prices move both stocks.
Next checkpoint: Q4 2026 results, if Range still reports (Jan 27, 2027 (estimate))
Below intrinsic value · Analysts: Leaning bullish
The market prices Raymond James for the risk to income on client cash and to fees when markets fall, and steady growth in client assets and client cash can close the gap over three to five quarters.
Next checkpoint: Fiscal Q1 2027 results: margins (Jan 28, 2027 (estimate))
Below intrinsic value · Analysts: Leaning bullish
Infant-formula lawsuits, a slow Mead Johnson sale and a cut to 2026 growth guidance hold the price down, and a return to target growth with a completed sale can close the gap within a year.
Next checkpoint: Investor event: Reckitt Focus On North America (Nov 19, 2026)
Below intrinsic value · Analysts: Mixed
The market prices SK Telecom for slow growth, the cost of the 2025 breach and a large AI data center plan, and steady profit with partner funding such as the SK Horizon sale can close the gap.
Next checkpoint: Q4 2026 and full-year results (Feb 4, 2027 (estimate))
Below intrinsic value · Analysts: Bullish
The market prices Sempra for California wildfire risk and the cost of a $65 billion building plan, and a closed KKR sale with steady utility growth over three to six quarters can close the gap.
Next checkpoint: KKR sale closes (Nov 19, 2026 (estimate))
Below intrinsic value · Analysts: Leaning bullish
The market prices Synchrony for the risk of higher card loan losses and its dependence on a few large partners, and stable credit with faster loan growth over three to five quarters can close the gap.
Next checkpoint: Q4 2026 results and the 2027 outlook (Jan 20, 2027 (estimate))
Below intrinsic value · Analysts: Leaning bullish
The market fears the debt and the antitrust risk of the Jetro Restaurant Depot deal, and a timely closing with falling leverage over four to eight quarters can close the gap.
Next checkpoint: Q2 fiscal 2027 results: local volume and deal closing (Feb 3, 2027 (estimate))
Below intrinsic value · Analysts: Bullish
The market fears that SpaceX will become a fourth national carrier, and steady account growth, low churn and cash flow on guidance over two to three years can close the gap.
Next checkpoint: Q4 2026 results and 2027 guidance (Jan 28, 2027 (estimate))
Below intrinsic value · Analysts: Leaning bullish
The market fears TransDigm's high and costlier debt while acquisitions dilute margins, and fiscal 2027 results at the outlook with rising margins over four to six quarters can close the gap.
Next checkpoint: Fiscal Q1 2027 results: margins of new businesses (Feb 10, 2027 (estimate))
Below intrinsic value · Analysts: Bullish
Rising rates enlarge the bank's bond losses and slow its buybacks, and a margin that keeps rising through 2027 with buybacks restarted can close the gap.
Next checkpoint: Q4 2026 results and 2027 outlook (Jan 15, 2027 (estimate))
Below intrinsic value · Analysts: Bullish
The market still prices UnitedHealth as a troubled business, and a low medical care ratio without reserve help and a mild result in the DOJ billing case can close the gap over two to four quarters.
Next checkpoint: 2027 earnings outlook (Dec 2026 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
The market doubts that Airbnb can keep its growth and margins against city rules, new spending and AI travel agents, and double-digit night growth with steady free cash flow can close the gap in four to six quarters.
Next checkpoint: Q4 2026 results and 2027 outlook (Feb 11, 2027 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
The market prices Align for slow growth and pressure from cheaper aligners, and steady volume growth with savings from the review pushed by Elliott can close the gap over three to six quarters.
Next checkpoint: Q4 2026 results, the operating model review and the new CEO's plan (Jan 28, 2027 (estimate))
Close to intrinsic value · Analysts: Very bullish
The market fears that record AI spending will not pay back, and higher AWS margins and backlog that turns into revenue over the next four to six quarters can close the gap.
Next checkpoint: EU decision on AWS as a Digital Markets Act gatekeeper (Nov 2026 (estimate))
Close to intrinsic value · Analysts: Bullish
The market prices Ameren for a costly building plan paid partly with new shares, and a fair Missouri rate order by May 2027 with new data center demand from late 2027 can close the gap.
Next checkpoint: Q4 2026 earnings: 2027 guidance (Feb 5, 2027 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
Investors fear that costs grow faster than revenue and that regulation cuts card profits, and slower cost growth with steady 2027 guidance can close the gap.
Next checkpoint: Q4 2026 results and 2027 guidance (Jan 23, 2027 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
América Móvil trades close to its intrinsic value because investors pay for its postpaid and broadband growth, and steady growth with a stable peso and no new rules in Mexico can keep it there.
Next checkpoint: Q4 2026 results (Feb 10, 2027 (estimate))
Close to intrinsic value · Analysts: Bullish
The market fears losses and withdrawals in private credit and a squeeze on Athene's spread, and steady fee growth with stable spread earnings over the next four quarters can close the gap.
Next checkpoint: Full-year 2026 report and 2027 targets (Feb 3, 2027 (estimate))
Close to intrinsic value · Analysts: Bullish
Investors doubt the AI ad story of AppLovin after a delayed product and a lawsuit, and better execution and e-commerce results over the next two to four quarters can close the gap.
Next checkpoint: Lead-plaintiff deadline in the securities class action (Nov 16, 2026)
Close to intrinsic value · Analysts: Bullish
After three large trial failures in 2026, the market doubts the 2030 revenue goal, and good trial results with steady growth over the next four to six quarters can close the gap.
Next checkpoint: FY 2026 results and 2027 guidance (Feb 9, 2027)
Close to intrinsic value · Analysts: Mixed
The market prices Atmos as a safe gas utility that must keep issuing shares and debt, and steady EPS growth under its new five-year plan with fair rate outcomes in Texas can close the gap.
Next checkpoint: Fiscal Q1 2027 earnings: rate outcomes (Feb 4, 2027 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
The market doubts that Santander can keep higher returns with Latin American risk and two large purchases, and 2026 targets met with RoTE rising toward the 2028 target can close the gap.
Next checkpoint: Full-year 2026 results and capital (Jan 28, 2027 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
The market prices Barclays for a volatile investment bank and a history of low returns, and higher returns on the way to the 2028 targets with large capital returns can close the gap within two years.
Next checkpoint: Full year 2026 results: return and capital returns (Feb 9, 2027 (estimate))
Close to intrinsic value · Analysts: Very bullish
Investors doubt how long BRUKINSA can carry BeOne's fast growth before its main patent ends in 2034, and only new approvals and a rising margin can lift its value.
Next checkpoint: ASH 2026: MANGROVE results in first-line mantle cell lymphoma (Dec 2026 (estimate))
Close to intrinsic value · Analysts: Bullish
BD trades close to its intrinsic value because investors weigh stable demand and cash flow against slow growth and quality problems, and faster growth with lower debt can lift the value.
Next checkpoint: Investor Day (Dec 10, 2026)
Close to intrinsic value · Analysts: Bullish
Investors watch whether Block's fast profit growth after its 2026 restructuring can last, and steady Cash App growth with low loan losses can support a higher value.
Next checkpoint: Q4 2026 results and the 2027 guidance (Feb 24, 2027)
Close to intrinsic value · Analysts: Bullish
US electrophysiology and WATCHMAN sales now fall as competitors gain, and a cyber incident hurt 2026, so sales must stop falling and grow again by 2028 for the gap to close.
Next checkpoint: Q4 2026 earnings and 2027 guidance (Jan 28, 2027 (estimate))
Close to intrinsic value · Analysts: Very bullish
Many investors do not own tobacco, so part of the gap will probably stay, and the rest can close only if New Category margins keep rising and leverage returns inside BAT's target range.
Next checkpoint: Pre-close trading update: 2026 guidance and leverage (Dec 2026 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
The market weighs the steady rate base growth of CMS Energy against its large debt and the need for new shares, and fair Michigan rate orders through 2027 can lift its value.
Next checkpoint: Q4 2026 results and 2027 outlook (Feb 4, 2027 (estimate))
Close to intrinsic value · Analysts: Bullish
The market doubts that Capital One can keep high returns with card rate caps under debate and two deals to integrate, and stable credit with Discover synergies and steady buybacks can close the gap within two years.
Next checkpoint: Q4 2026 results: credit and buybacks (Jan 21, 2027 (estimate))
Close to intrinsic value · Analysts: Bullish
Cencora trades close to its intrinsic value because investors pay a full price for its steady growth but weigh opioid settlements and debt, and specialty growth as guided can lift the value.
Next checkpoint: Q1 fiscal 2027 results (Feb 3, 2027 (estimate))
Close to intrinsic value (AI estimate) · Analysts: Bullish
The market prices Cenovus close to the AI estimate on doubts that the high oil prices and refining margins of 2026 can last, and only steady oil sands growth with low costs and buybacks can lift its value.
Next checkpoint: Closing of the Athabasca Oil purchase (Dec 2026 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
The market prices Centene as a health insurer with thin margins and heavy exposure to government programs, and falling medical costs with a 2027 outlook above 2026 can lift its value.
Next checkpoint: Q4 2026 results and 2027 outlook (Feb 5, 2027 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
The market prices CenterPoint for the cost of a large building plan and Houston storm risk, and timely cost recovery with new large-load connections over the next four to six quarters can close the gap.
Next checkpoint: Full-year 2026 results and 2027 guidance (Jan 27, 2027 (estimate))
Close to intrinsic value · Analysts: Bullish
The market doubts that Citigroup can earn returns above its cost of equity, and returns in its target range for 2027 with lower expenses and steady buybacks can close the gap.
Next checkpoint: Q4 2026 results: returns and 2027 outlook (Jan 14, 2027)
Close to intrinsic value · Analysts: Very bullish
The market doubts that revenue growth and margins keep rising while lawsuits are open, and steady growth from the G7 15 Day system and from users of type 2 diabetes can lift its value.
Next checkpoint: Q4 2026 results and guidance for 2027 (Feb 11, 2027 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
The market doubts that margins keep rising while an FTC lawsuit is open, and steady same-store sales with a small settlement can lift its value.
Next checkpoint: Q3 fiscal 2026 results: margin and traffic (Dec 3, 2026 (estimate))
Close to intrinsic value · Analysts: Mixed
Dominion now trades as a fixed share of NextEra plus deal risk, so the gap closes only if NextEra shares rise or the merger fails and Dominion is valued on its own again.
Next checkpoint: Virginia SCC decision on the merger (Jan 11, 2027 (estimate))
Close to intrinsic value · Analysts: Bullish
The market prices DuPont for its legacy PFAS liabilities and doubts about the smaller company after its spin-off and sale, and steady growth with contained PFAS costs through 2027 can close the gap.
Next checkpoint: Full-year 2026 results and 2027 guidance (Feb 3, 2027 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
The market prices Duke Energy for a very large building plan paid with debt and new shares, and fair North Carolina rate orders with steady earnings growth through 2027 can close the gap.
Next checkpoint: North Carolina rate case orders (Nov 2026 (estimate))
Close to intrinsic value · Analysts: Very bullish
The market weighs the cash from the AT&T sale and the SpaceX shares due in 2027 against the debts and claims in its bankrupt units, and a clean exit from those cases can lift its value.
Next checkpoint: 10-K for 2026 (Mar 1, 2027 (estimate))
Close to intrinsic value · Analysts: Mixed
The market prices Eversource for a lower FERC return and hard rate cases in Connecticut, and a fair CL&P decision in mid-2027 with steady earnings growth can close the gap.
Next checkpoint: FERC decision on a new transmission return on equity (Dec 2026 (estimate))
Close to intrinsic value · Analysts: Mixed
The market prices Exelon for political pressure on utility bills and the new shares it must sell, and fair rate decisions with earnings growth near the top of its range can close the gap.
Next checkpoint: Q4 2026 results: 2027 guidance and updated capital plan (Jan 30, 2027 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
The housing regulator now prices FICO and the cheaper VantageScore the same, and the gap closes only if mortgage score revenue holds up as lenders choose over the next several years.
Next checkpoint: Fiscal Q1 2027 results: first full quarter of the single pricing grid (Feb 4, 2027 (estimate))
Close to intrinsic value · Analysts: Bullish
The market doubts that Fifth Third can earn a good return on the Comerica purchase while deposit costs rise, and the full cost savings with steady credit and the 2027 return targets can lift its value.
Next checkpoint: Q4 2026 results and 2027 outlook (Jan 19, 2027 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
The market doubts how long US tax credits and trade rules will protect First Solar, and stronger bookings after the new minimum import prices through 2027 can lift its value.
Next checkpoint: Section 232 minimum import prices start (Dec 4, 2026)
Close to intrinsic value · Analysts: Leaning bullish
The market prices FirstEnergy for high debt and the cost of the Ohio scandal, and a fair Ohio rate plan with new data center investment can close the gap over two to four quarters.
Next checkpoint: West Virginia order on the Maidsville Energy Center (Q4 2026 (estimate))
Close to intrinsic value · Analysts: Bullish
The market weighs strong news and sports earnings against the debt and new shares of the Roku purchase, and a Roku that adds earnings with the planned cost savings can lift its value.
Next checkpoint: Roku financial statements and pro forma information (Form 8-K/A) (Jan 2027 (estimate))
Close to intrinsic value · Analysts: Bullish
The market prices GE Aerospace for strong engine services but also for a costly castings deal, lower engine margins and insurance charges, and years of steady services growth can close the gap slowly.
Next checkpoint: Q4 2026 results and 2027 guidance (Jan 21, 2027 (estimate))
Close to intrinsic value · Analysts: Bullish
GM trades close to its intrinsic value because investors weigh strong truck profits and buybacks against tariffs and EV costs, and steady margins with lower tariff costs can lift the value.
Next checkpoint: Q4 2026 results and 2027 guidance (Jan 26, 2027 (estimate))
Close to intrinsic value (AI estimate) · Analysts: Bullish
The market prices Gold Fields close to the AI estimate, on a gold price that can fall and on the risk that Ghana does not renew its Tarkwa leases, and only a lease renewal with costs inside guidance can keep it there.
Next checkpoint: 2026 results and Windfall decision (Feb 19, 2027 (estimate))
Close to intrinsic value · Analysts: Bullish
The market expects Humana's earnings to recover by 2028 after the fall in its Star Ratings, and only higher Medicare Advantage margins with stable rates and audits can support this view.
Next checkpoint: Investor update: the path to 2028 (Dec 10, 2026)
Close to intrinsic value · Analysts: Very bullish
The market prices IDACORP for the new shares that fund its large building plan and for wildfire risk, and EPS within guidance with timely rate increases can close the small gap within a year.
Next checkpoint: Q4 2026 results and the 2027 guidance (Jan 29, 2027 (estimate))
Close to intrinsic value · Analysts: Bullish
Itaú Unibanco trades close to its intrinsic value because investors pay for high returns but price the risks of Brazil, and steady returns with sound credit quality can keep it there.
Next checkpoint: Q4 2026 results and 2027 guidance (Feb 3, 2027 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
Investors pay a premium for JPMorgan's high and steady returns, and returns that stay high when trading slows and credit losses rise can earn it.
Next checkpoint: Q4 2026 results and 2027 guidance (Jan 14, 2027)
Close to intrinsic value (AI estimate) · Analysts: Very bullish
The market prices KB Financial Group close to the AI estimate on doubts that it can keep its profit after the charges of 2025, and steady profit with dividends and buybacks under the new chairman can lift its value.
Next checkpoint: Extraordinary general meeting: new Chairman (Nov 20, 2026)
Close to intrinsic value · Analysts: Bullish
The market prices KKR for the risk of private credit losses and slower fundraising, and steady fee growth, low credit losses, stronger fundraising and more asset sales can close the gap over four to eight quarters.
Next checkpoint: Q4 2026 results, the USI sale and fundraising (Feb 9, 2027 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
The market prices KT for low returns, a security incident and large investment plans, and higher margins with buybacks toward the 2028 value-up targets can close the gap slowly.
Next checkpoint: Full-year 2026 results: wireless recovery (Feb 10, 2027 (estimate))
Close to intrinsic value (AI estimate) · Analysts: Bullish
The market expects Marex to keep most of its record 2026 profit, so the price holds only if profit grows in quarters of normal volatility and the control weaknesses are fixed.
Next checkpoint: Q4 2026 results and the 2027 growth target (Feb 5, 2027 (estimate))
Close to intrinsic value · Analysts: Bullish
The market prices Medline for a cut to its profit guidance, the Tracy fire and sales by its private equity owners, and results on the new guidance with good insurance recoveries can close the gap.
Next checkpoint: Tracy fire insurance and 2027 guidance (Feb 4, 2027 (estimate))
Close to intrinsic value · Analysts: Bullish
The market doubts that Medtronic can keep its faster growth, and results on the raised fiscal 2027 guidance with strong cardiac ablation growth over two to four quarters can close the gap.
Next checkpoint: Q2 fiscal 2027 earnings: growth without the extra week (Nov 24, 2026)
Close to intrinsic value · Analysts: Bullish
The market doubts that Merck can replace Keytruda sales before biosimilars and Medicare price setting from late 2028, and strong launches and late-stage results through 2028 can close the gap.
Next checkpoint: Q4 2026 results and 2027 guidance (Feb 2, 2027 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
The market doubts that Morgan Stanley's high returns last when trading and deals slow, and returns that stay near its goal through 2027 can close the gap.
Next checkpoint: Q4 2026 results: returns and wealth flows (Jan 15, 2027 (estimate))
Close to intrinsic value · Analysts: Very bullish
The market prices Nexstar for the lawsuit against its TEGNA purchase and its higher debt, and a court result that lets it combine TEGNA with steady debt repayment over the next six to eight quarters can close the gap.
Next checkpoint: Ninth Circuit hearing on the TEGNA injunction (Q4 2026 (estimate))
Close to intrinsic value · Analysts: Bullish
The market prices NextEra Energy for the cost and approval risk of its Dominion Energy deal, and approvals without large new conditions and steady EPS growth over the next four to six quarters can close the gap.
Next checkpoint: FPL signs its first large-load contract (Dec 2026 (estimate))
Close to intrinsic value · Analysts: Mixed
The market fears that Novo is losing the obesity-drug race to Lilly, and a CagriSema approval in Q4 2026 with more Wegovy pill growth can close the gap.
Next checkpoint: FDA decision on CagriSema for obesity (Q4 2026 (estimate))
Close to intrinsic value · Analysts: Bullish
The market prices PNC for rate risk and weaker commercial credit after the FirstBank purchase, and a higher margin with stable loan losses over the next two to four quarters can close the gap.
Next checkpoint: Q4 2026 earnings: margin and credit (Jan 15, 2027 (estimate))
Close to intrinsic value · Analysts: Bullish
The market doubts that PPL can turn data center demand into investment with a fair return, and signed supply deals with a Kentucky generation filing by early 2027 can close the gap.
Next checkpoint: Invitium Energy supply agreement (Dec 2026 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
The market prices Petrobras for state control of fuel prices and investment, and steady dividends with record pre-salt output can close part of the gap, but state control probably keeps the rest.
Next checkpoint: 2027-2031 Business Plan (Nov 2026 (estimate))
Close to intrinsic value · Analysts: Mixed
The market fears that patent losses and lower US drug prices will shrink Pfizer's revenue, and only steady growth of new medicines and good obesity data over several years can close the gap.
Next checkpoint: 2027 guidance (Dec 2026 (estimate))
Close to intrinsic value · Analysts: Bullish
The market doubts that IQOS and ZYN can grow fast enough to offset falling cigarette volumes and high debt, and 2027 guidance that meets PMI's targets can close the gap.
Next checkpoint: Q4 2026 results and 2027 guidance (Feb 5, 2027 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
The market prices PSEG for political pressure on New Jersey power bills, and steady guidance with a fair result from the state utility review in 2027 can close the gap.
Next checkpoint: Mandatory RTO membership: transmission return adder (Jan 2027 (estimate))
Close to intrinsic value · Analysts: Mixed
QIAGEN now trades on a pending EUR 46.50 per share cash offer from EQT, and tender acceptance, the shareholder vote and regulatory clearances before a close in mid-2027 decide the outcome.
Next checkpoint: BaFin approves the offer document and acceptance starts (Dec 2026 (estimate))
Close to intrinsic value (AI estimate) · Analysts: Bullish
RWE trades close to the AI estimate because investors pay for its large build-out of wind, solar, batteries and gas plants, and only projects that earn their planned returns without many new shares can keep it there.
Next checkpoint: 2026 annual report and 2027 guidance (Mar 4, 2027)
Close to intrinsic value · Analysts: Bullish
The market doubts that Roche's new medicines can replace sales lost to biosimilars, and good launches such as giredestrant over the next four quarters can close the gap.
Next checkpoint: FDA decision on giredestrant in early breast cancer (Nov 30, 2026)
Close to intrinsic value · Analysts: Bullish
The market prices Royalty Pharma on the end of some royalties and its large debt, and new royalty purchases that replace those cash flows can lift its value.
Next checkpoint: Q4 2026 results and 2027 guidance (Feb 10, 2027 (estimate))
Close to intrinsic value
The market priced Société Générale with caution after years of low returns, and only high returns that last after 2026, also in weaker markets, can show that the turnaround holds.
Next checkpoint: FY 2026 results and distribution (Feb 4, 2027)
Close to intrinsic value (AI estimate) · Analysts: Bullish
Strategy's shares follow the bitcoin price with leverage, and the AI estimate, the value of its bitcoins less its debt and preferred stock, moves with that price every day.
Next checkpoint: Q4 2026 results and the USD Reserve (Jan 29, 2027 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
The market prices TIM Brasil for the risks of Brazil and a new controlling shareholder, and steady service growth with high payouts can close the gap slowly over one to two years.
Next checkpoint: 2026 results, the 2027 plan and the shareholder payout (Feb 9, 2027 (estimate))
Close to intrinsic value · Analysts: Bullish
The market weighs the fast earnings growth of Tenet in ambulatory surgery and hospitals against Medicaid payment limits and lower exchange volumes, and 2027 earnings that hold up can lift its value.
Next checkpoint: Q4 2026 results and 2027 outlook (Feb 10, 2027 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
The market prices Tesla mostly for robotaxis and robots while its car margins are thin, and only years of growth in autonomy revenue with a margin recovery can close the gap slowly.
Next checkpoint: 2026 annual meeting votes (Dec 3, 2026)
Close to intrinsic value · Analysts: Bullish
The market fears that pressure on pharmacy benefit managers will cut Cigna's profits, and steady specialty growth with stable pharmacy margins over the next four to six quarters can close the gap.
Next checkpoint: 2027 outlook (Feb 5, 2027 (estimate))
Close to intrinsic value · Analysts: Mixed
The market prices CooperCompanies for slow contact lens growth after a strategic review that kept CooperSurgical, and a return to CooperVision growth in fiscal 2027 can close the gap.
Next checkpoint: Q4 fiscal 2026 earnings and fiscal 2027 guidance (Dec 3, 2026)
Close to intrinsic value (AI estimate) · Analysts: Leaning bullish
Tokio Marine trades close to the AI estimate because investors pay for growth abroad but doubt profit in Japan, and steady buybacks with rising returns can keep it there.
Next checkpoint: First-half fiscal 2026 results (Nov 19, 2026 (estimate))
Close to intrinsic value · Analysts: Bullish
The market prices TransUnion for changes in US mortgage credit scoring, the credit cycle and its debt, and steady organic growth with lower leverage over three to five quarters can close the gap.
Next checkpoint: 2026 results and the 2027 guidance (Jan 27, 2027 (estimate))
Close to intrinsic value · Analysts: Bullish
The market prices UBS for much higher Swiss capital rules, and a softer rule from Parliament with the integration targets met at the end of 2026 can close the gap.
Next checkpoint: National Council debate on foreign subsidiaries (Dec 2026 (estimate))
Close to intrinsic value · Analysts: Bullish
The slow Foods separation with McCormick and currency losses hold Unilever's price down, and steady volume-led growth with a deal close by mid-2027 can close the gap.
Next checkpoint: Parties' answer to the UK competition finding (Nov 18, 2026 (estimate))
Close to intrinsic value · Analysts: Mixed
The market prices UHS for cuts to Medicaid supplemental payments and new regulatory actions, and steady volume growth with results near the revised 2026 guidance can close the gap.
Next checkpoint: 2026 results and 2027 guidance (Jan 27, 2027 (estimate))
Close to intrinsic value · Analysts: Leaning bullish
The market doubts that Venture Global can carry its debt and the costs of its customer disputes, and a start of Plaquemines Phase 2 and CP2 in mid-2027 can lift its value.
Next checkpoint: Q4 2026 results and 2027 outlook (Mar 1, 2027 (estimate))
Close to intrinsic value · Analysts: Bullish
Investors fear that AI weakens Verisk's data and that a court will force the AccuLynx deal, and a growth recovery with an end to the case over four to six quarters can close the gap.
Next checkpoint: Full-year 2026 results and 2027 guidance (Feb 5, 2027 (estimate))
Close to intrinsic value · Analysts: Bullish
The market doubts the new spin-off Vylor because it has no stand-alone record and faces a lawsuit against its separation, and clean first reports, a court win and the start of dividends can lift its value.
Next checkpoint: Form 10-Q for Q3 2026: first results as an independent company (Nov 16, 2026 (estimate))
Close to intrinsic value · Analysts: Mixed
The market prices WEC for a record capital plan that depends on a few data center customers, and fair rate orders in late 2026 with data center load on plan can close the gap.
Next checkpoint: Wisconsin and Illinois rate orders (Dec 2026 (estimate))
Close to intrinsic value (AI estimate) · Analysts: Leaning bullish
Investors price Walmex close to the AI estimate as a strong retailer whose growth has slowed in a weak Mexican economy, and only faster same-store sales with a stable margin can lift its value.
Next checkpoint: Q4 2026 results and 2027 guidance (Feb 16, 2027)
Close to intrinsic value (AI estimate) · Analysts: Very bullish
Investors pay more than the AI estimate for high gold and silver prices and the growth plan of Wheaton, and only high metal prices with production near 1,200,000 GEOs by 2030 can earn this price.
Next checkpoint: 2026 production and 2027 guidance (Feb 2027 (estimate))
Pricey · Analysts: Bullish
Investors pay a premium for Abbott's steady growth in devices and diagnostics, and only faster glucose monitor growth, lower debt and a clean Nutrition separation can earn it.
Next checkpoint: Q4 2026 results and 2027 guidance (Jan 21, 2027 (estimate))
Pricey · Analysts: Bullish
Agilent's price already includes a lasting recovery in laboratory demand, and only steady core growth with a rising margin and a good return on Biocare can support this price.
Next checkpoint: Q4 fiscal 2026 results and fiscal 2027 guidance (Nov 23, 2026)
Pricey · Analysts: Bullish
The market doubts that the cancer pipeline of BioNTech can replace its falling COVID-19 vaccine sales, and positive Phase 3 data for pumitamig and gotistobart through 2028 can lift its value.
Next checkpoint: Gotistobart Phase 3 interim analysis (Dec 2026 (estimate))
Pricey · Analysts: Leaning bullish
Investors pay a premium for the rail network and pricing of CN, and volume growth with new labor agreements and open trade between Canada and the United States can earn it.
Next checkpoint: Q4 2026 results and 2027 guidance (Jan 29, 2027 (estimate))
Pricey · Analysts: Bullish
Investors pay a premium for the fast profit growth and the buybacks of Cardinal Health, and only strong growth after fiscal 2027 with a final CVS Health agreement can earn it.
Next checkpoint: Q2 fiscal 2027 results (Feb 4, 2027 (estimate))
Pricey · Analysts: Bullish
The market weighs the growth of Coca-Cola FEMSA in Brazil and Colombia against a much higher sugar tax in Mexico and weak currencies, and stable Mexican volume through 2027 can lift its value.
Next checkpoint: Q4 2026 results (Feb 23, 2027 (estimate))
Pricey (AI estimate) · Analysts: Bullish
Investors pay more than the AI estimate for Franco-Nevada's debt-free, diversified gold royalties, and only steady growth in ounces with a high gold price and a Cobre Panamá restart can support this price.
Next checkpoint: Côté Gold royalty buyback (Dec 2026 (estimate))
Pricey · Analysts: Bullish
The market weighs whether a string of acquisitions and payment rules for tests let earnings keep growing, and steady organic growth with deals that add earnings can lift its value.
Next checkpoint: Q4 2026 results and guidance for 2027 (Feb 16, 2027 (estimate))
Pricey · Analysts: Leaning bullish
The market doubts that Quest can keep double-digit volume growth and margin gains after its October data incident, and steady testing growth through 2027 can lift its value.
Next checkpoint: Q4 2026 results and 2027 outlook (Feb 9, 2027 (estimate))
Pricey · Analysts: Bullish
The market doubts that Regeneron can replace lost EYLEA sales and depend less on Dupixent, and EYLEA HD growth with new approvals such as cemdisiran through 2027 can close the gap.
Next checkpoint: FDA decision on cemdisiran in generalized myasthenia gravis (Nov 2026)
Pricey · Analysts: Bullish
The market prices STERIS for slower sterilization services growth, tariffs and the debt for its Xodus purchase, and steady organic growth with a clean close can close the gap over three to five quarters.
Next checkpoint: Xodus purchase closes (Dec 31, 2026 (estimate))
Pricey (AI estimate) · Analysts: Bullish
Investors pay more than the AI estimate for the record cash flow and buybacks of Suncor at high oil prices, and only oil prices well above the 2025 average can keep the price there.
Next checkpoint: Q4 2026 results and 2027 plan (Feb 2, 2027 (estimate))
Pricey (AI estimate) · Analysts: Very bullish
The market prices TKO close to the AI estimate, and only Adjusted EBITDA that keeps rising in 2027 after the one-time gains of 2026, with debt funded buybacks under control, can keep it there.
Next checkpoint: Q4 2026 events held as planned (Q4 2026 (estimate))
Pricey · Analysts: Bullish
Vertex trades at a premium because investors pay for its hold on cystic fibrosis and new medicines after it, and approval of povetacicept with good 2027 study results can earn it.
Next checkpoint: FDA decision on povetacicept in IgA nephropathy (Nov 30, 2026)
Pricey · Analysts: Bullish
The market doubts that Viatris can return to growth while its Nashik plant is shut and generic prices stay under pressure, and the restart of the plant and the Pacira purchase through 2027 can lift its value.
Next checkpoint: Pacira purchase closes (Nov 2026 (estimate))
Pricey · Analysts: Very bullish
Investors pay a premium for the fast growth of VYVGART and the pipeline of argenx, and positive Phase 3 results with new indications can earn it.
Next checkpoint: Phase 3 EMPASSION results of empasiprubart in MMN (Dec 2026 (estimate))
Far above intrinsic value · Analysts: Leaning bullish
Investors pay a premium for 3M's margin turnaround and its PFAS settlement, and only strong claimant participation with steady EPS growth in 2027 can earn it.
Next checkpoint: Q4 2026 results and 2027 guidance (Jan 19, 2027 (estimate))
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for AbbVie's fast growth from Skyrizi and Rinvoq, and steady growth of these medicines with new launches and lower debt can earn it.
Next checkpoint: Full-year 2026 results and 2027 guidance (Feb 3, 2027 (estimate))
Far above intrinsic value · Analysts: Leaning bullish
Investors pay a premium for high copper prices and the planned merger of Anglo American with Teck, and only high copper prices with the expected synergies can earn it.
Next checkpoint: Full-year 2026 results (Feb 19, 2027 (estimate))
Far above intrinsic value · Analysts: Bullish
AngloGold Ashanti trades above its intrinsic value because investors pay for its gold cash flow and cash returns, and only lower unit costs, on-time growth projects and steady repurchases can support this price.
Next checkpoint: North Bullfrog permits and Guinea refining rule (Q4 2026 (estimate))
Far above intrinsic value · Analysts: Leaning bullish
Investors pay a premium for Apple's steady cash flow and Services growth, and the premium holds only if margins stay firm as memory costs rise and courts leave its Services profit intact.
Next checkpoint: Q1 fiscal 2027 results: margin and iPhone cycle (Feb 2, 2027 (estimate))
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for the steady organic growth and acquisitions of Gallagher, and only many years of growth with higher margins can earn it.
Next checkpoint: Q4 2026 results and 2027 outlook (Jan 29, 2027 (estimate))
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for the high gold price, the buybacks and the planned listing of North American Barrick, and only a high gold price with a successful listing can earn it.
Next checkpoint: Q4 2026 results and 2027 guidance (Feb 9, 2027 (estimate))
Far above intrinsic value · Analysts: Bullish
The market doubts that new products can replace falling multiple sclerosis sales after the large Apellis deal, and the lupus data in December 2026 and steady growth of new products can lift its value.
Next checkpoint: TOPAZ-1 and TOPAZ-2: litifilimab in lupus (Dec 2026 (estimate))
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for the fast margin recovery at CSX under its new chief executive, and only higher margins, volume growth and better service through 2027 can earn it.
Next checkpoint: Q4 2026 results and 2027 outlook (Jan 21, 2027 (estimate))
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for the three-country rail network of CPKC, and only years of volume and earnings growth while trade between Canada, the United States and Mexico stays open can earn it.
Next checkpoint: Q4 2026 results and 2027 guidance (Jan 27, 2027 (estimate))
Far above intrinsic value · Analysts: Leaning bullish
Investors pay a premium for the steady growth and rising margins of Cintas and the UniFirst savings, and an FTC suit or slower hiring at customers can shrink it.
Next checkpoint: Q2 fiscal 2027 results (Dec 17, 2026 (estimate))
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for Coca-Cola's brands and steady growth, and organic growth near the 2026 pace with no large IRS tax bill can earn it over several years.
Next checkpoint: Sale of bottling operations in Africa (Q4 2026 (estimate))
Far above intrinsic value · Analysts: Leaning bullish
Investors pay a premium for the higher profits and payouts of Deutsche Bank, and only returns on tangible equity that reach its 2028 target can earn it.
Next checkpoint: FY 2026 results and payouts (Jan 28, 2027 (estimate))
Far above intrinsic value · Analysts: Very bullish
Investors pay a premium for the leading position of Edwards in TAVR and the fast growth of its mitral and tricuspid therapies, and only several years of fast sales growth with higher margins can earn it.
Next checkpoint: Q4 2026 results and 2027 guidance (Feb 4, 2027 (estimate))
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for Lilly's fast growth in obesity medicines, and the premium holds only if 2027 volume growth outpaces price cuts and the retatrutide filing stays on time.
Next checkpoint: Q4 2026 results and 2027 guidance (Jan 29, 2027 (estimate))
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for the copper reserves and growth projects of Freeport-McMoRan, and only a high copper price with a full Grasberg recovery by the end of 2027 can earn it.
Next checkpoint: Q4 2026 results and 2027 outlook (Jan 21, 2027 (estimate))
Far above intrinsic value (AI estimate) · Analysts: Very bullish
Investors pay more than the AI estimate for the new medicines of Genmab, and only approvals of petosemtamab and Rina-S with sales that replace DARZALEX royalties can earn this price.
Next checkpoint: 2026 annual results and 2027 guidance (Feb 16, 2027 (estimate))
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for Gilead's growing HIV business, and fast growth of Yeztugo and Descovy with good new launches before the Biktarvy Medicare price in 2028 can earn it.
Next checkpoint: FDA decision on anito-cel in multiple myeloma (Dec 23, 2026)
Far above intrinsic value · Analysts: Leaning bullish
Investors pay a premium for HCA's scale and buybacks, and only 2027 guidance for higher earnings despite fewer insured patients can earn it.
Next checkpoint: Q4 2026 results and 2027 guidance (Jan 27, 2027 (estimate))
Far above intrinsic value (AI estimate) · Analysts: Very bullish
HDFC Bank trades at a premium to the AI estimate because investors pay for its long growth record, and higher returns with no new governance problems under its new leaders can earn it.
Next checkpoint: Q3 fiscal 2027 results: profit growth and margin (Jan 16, 2027 (estimate))
Far above intrinsic value (AI estimate) · Analysts: Very bullish
ICICI Bank trades at a premium to the AI estimate because investors pay for its high returns and fast loan growth, and a steady margin with few bad loans can earn it.
Next checkpoint: Q3 fiscal 2027 results: margin and asset quality (Jan 16, 2027 (estimate))
Far above intrinsic value · Analysts: Leaning bullish
Investors pay a premium for the fast growth of Opzelura and blood cancer drugs at Incyte, and only positive Phase 3 data and approvals through 2027 that replace Jakafi after 2028 can earn this price.
Next checkpoint: Phase 3 data for povorcitinib in prurigo nodularis and ruxolitinib cream in hidradenitis suppurativa (Q4 2026 (estimate))
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for Intuitive's lead in robotic surgery, and procedure growth in the mid-teens with stable margins against new competitors can earn it.
Next checkpoint: Q4 2026 results and 2027 outlook (Jan 20, 2027 (estimate))
Far above intrinsic value (AI estimate) · Analysts: Leaning bullish
Japan Tobacco trades close to the AI estimate because investors weigh strong pricing and Ploom growth against the possible loss of its Russian business, and a limited loss of profit from Russia can keep it there.
Next checkpoint: Effect of the Russian decree (Dec 2026 (estimate))
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for Johnson & Johnson's steady growth and pipeline, and the 2027 outlook, the talc settlement and the Orthopaedics separation show whether growth can earn it.
Next checkpoint: Enterprise Business Review: growth plan (Dec 8, 2026)
Far above intrinsic value · Analysts: Bullish
Live Nation trades above its intrinsic value because investors pay for record concert demand, and only remedies that leave Ticketmaster intact with steady growth in concert profit can support this price.
Next checkpoint: Q4 2026 results: 2026 AOI and 2027 outlook (Feb 18, 2027 (estimate))
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for the steady earnings growth and buybacks of Loblaw, and only several years of EPS growth near its long-term target can earn it.
Next checkpoint: Q3 2026 results, the first quarter without President's Choice Bank (Nov 19, 2026)
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for Mastercard's steady network growth and high margins, and growth near the low teens with stable fees after the merchant settlement can earn it.
Next checkpoint: Final approval of the US merchant settlement (Nov 2026)
Far above intrinsic value · Analysts: Bullish
McKesson trades at a premium because investors pay for steady drug distribution profits and buybacks, and EPS growth at its long-term target with a clean Medical-Surgical separation can earn it.
Next checkpoint: Q3 fiscal 2027 results: EPS growth and guidance (Feb 3, 2027 (estimate))
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for the record earnings, high returns and buybacks of MetLife, and only several years of double-digit adjusted EPS growth can earn it.
Next checkpoint: Q4 2026 results and 2027 targets (Feb 4, 2027 (estimate))
Far above intrinsic value · Analysts: Leaning bullish
Investors pay a premium for the brand, the growth record and the cash of Monster, and only fast sales growth with stable margins as costs rise can earn it.
Next checkpoint: Q4 2026 results: margins and US growth (Feb 25, 2027 (estimate))
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for the fast growth of the software and index businesses of Nasdaq, and only several years of double-digit growth in recurring revenue and EPS can earn it.
Next checkpoint: Start of 23-hour trading on The Nasdaq Stock Market (Dec 6, 2026)
Far above intrinsic value (AI estimate) · Analysts: Very bullish
Natera trades above the AI estimate because investors pay for its fast growth in cancer testing, and only growing test volume with operating costs that rise slower than revenue can support this price.
Next checkpoint: Q4 2026 results: 2027 guidance and gross margin (Feb 25, 2027 (estimate))
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for the price increases and Greif mill gains of Packaging Corporation of America, and only prices that outrun rising freight and fiber costs through 2027 can earn this price.
Next checkpoint: Q4 2026 results and 2027 outlook (Jan 21, 2027 (estimate))
Far above intrinsic value · Analysts: Leaning bullish
Investors pay a premium for Phillips 66's record refining profit and steady Midstream cash, and only high margins through 2027 with debt on target can earn it.
Next checkpoint: Q4 2026 results and 2027 capital budget (Feb 3, 2027 (estimate))
Far above intrinsic value · Analysts: Bullish
The market fears a price war in Canadian wireless, and higher mobile revenue per user with steady subscriber growth and low debt over the next two to four quarters can close the gap.
Next checkpoint: Q4 2026 results: free cash flow (Feb 5, 2027 (estimate))
Far above intrinsic value · Analysts: Leaning bullish
Investors pay a premium for the landfills and steady price increases of Republic, and only many years of earnings growth with a return of volume can earn it.
Next checkpoint: Q4 2026 results and 2027 guidance (Feb 16, 2027 (estimate))
Far above intrinsic value (AI estimate) · Analysts: Very bullish
Revolution Medicines trades above the AI estimate because investors pay for how large its RAS drugs can grow, and only steady RASONQUE sales with positive first-line trials can support this price.
Next checkpoint: European Commission decision on daraxonrasib (Dec 2026 (estimate))
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for the fast growth in assets and new businesses of Robinhood, and only several years of fast earnings growth with legal event contracts can earn it.
Next checkpoint: Q4 2026 results (Feb 10, 2027 (estimate))
Far above intrinsic value (AI estimate) · Analysts: Bullish
Investors pay more than the AI estimate for the record backlog of Rocket Lab, and only a Neutron flight in 2027 with rising margins and a closed Iridium deal can earn this price.
Next checkpoint: Q4 2026 results: revenue and gross margin (Feb 25, 2027 (estimate))
Far above intrinsic value (AI estimate) · Analysts: Very bullish
Investors pay more than the AI estimate for the launch of LISRAYA and the late-stage pipeline of Roivant, and only approvals in uveitis and several IMVT-1402 diseases with strong sales can earn this price.
Next checkpoint: Investor Day (Dec 9, 2026)
Far above intrinsic value (AI estimate) · Analysts: Very bullish
Investors pay more than the AI estimate for the new medicines of Takeda, and only an FDA approval of zasocitinib with strong launches can earn this price.
Next checkpoint: Results for the nine months to December 2026 (Jan 28, 2027 (estimate))
Far above intrinsic value · Analysts: Leaning bullish
Investors pay a premium for TD's fast recovery in returns after its money laundering failures in the United States, and only returns that hold when markets slow and the remediation there ends can earn it.
Next checkpoint: Q4 fiscal 2026 results and fiscal 2027 targets (Dec 3, 2026)
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for Union Pacific's western rail network and the planned Norfolk Southern merger, and STB approval with steady EPS growth through 2027 can earn it.
Next checkpoint: STB comments on the merger due (Nov 18, 2026)
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for the steady .com fee rises and the sole registry of Verisign, and only domain growth with a fee rise each year through 2030 can earn this price.
Next checkpoint: .web roll-out (Dec 2026 (estimate))
Far above intrinsic value · Analysts: Bullish
Investors pay a premium for Visa's high-margin network, and steady revenue growth with no large new limits from courts or Congress can earn it over several years.
Next checkpoint: Q1 fiscal 2027 results: revenue growth (Jan 28, 2027 (estimate))
Far above intrinsic value · Analysts: Very bullish
Waste Connections' price already includes years of steady growth and a high margin, and only years of price increases above costs, acquisitions and repurchases can support this price.
Next checkpoint: Q4 2026 results and 2027 outlook (Feb 10, 2027 (estimate))
Far above intrinsic value · Analysts: Bullish
Investors pay for Xcel Energy's large capital plan and growth in power demand, and only fair rate outcomes and no new large wildfire losses can support this price.
Next checkpoint: Minnesota decision on the Rate Stability Plan (Jan 2027 (estimate))
Pass rate counts thesis checkpoints that came true. It is not an investment return. Past results do not predict future results.
Every result is on the checkpoints page.
Picks gives general opinions about stocks, including a "Top pick" label. They are not tailored to your needs, goals or risk tolerance. Kevin is not a registered adviser and relies on the general-advice exemption in Canadian securities law (NI 31-103 s.8.25). Do your own research, or ask a registered adviser. Kevin may hold any stock on this site. Read the Disclaimer.